Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
Abstract Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through several mechanisms, including complement-dependent cytotoxicity (CDC), ant...
Uloženo v:
| Hlavní autoři: | , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2016-06-01
|
| Edice: | Journal of Hematology & Oncology |
| On-line přístup: | http://link.springer.com/article/10.1186/s13045-016-0283-0 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|